{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:04:05Z","timestamp":1789560245626,"version":"build-2803163510"},"reference-count":67,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["100692800"],"award-info":[{"award-number":["100692800"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nectin-4 is a validated target for theranostic approaches toward urothelial carcinoma, and radiolabeled ligands for PET and SPECT imaging are gaining increasing interest for noninvasive quantification of Nectin-4 prior to a targeted therapy. The goal of this study was to develop bicyclic peptides that allow radiolabeling with three different radionuclides (61Cu, 64Cu, and 68Ga) and to evaluate their suitability for high-contrast PET imaging in urothelial carcinoma (UC) and triple-negative breast cancer (TNBC). For this purpose, NECT-330, NECT-334, and NECT-346 were designed based on our previously developed ligand NECT-224 but harbor additional linker units between the bicyclic scaffold and the radiometal chelator. Binding kinetics to recombinant Nectin-4 and related isoforms were assessed by surface plasmon resonance (SPR) interaction analysis. Nectin-4-specific cell binding of the radiolabeled probes was determined using UC and TNBC cell lines, and PET\/CT imaging was performed in respective tumor xenograft models. All novel ligands showed potent and selective binding to Nectin-4, with improved koff values compared to NECT-224. In small-animal PET\/CT imaging studies, the most favorable properties were observed for [64Cu]Cu-NECT-334 (tumor-to-muscle of 20.8 and tumor-to-heart of 11.2) and [64Cu]Cu-NECT-346 (tumor-to-muscle of 15.5 and tumor-to-heart of 8.7) 1\u20132 h postinjection using a HT-1376 tumor model. Although the novel radioligands provided superior imaging properties to the previously developed radioligand [64Cu]Cu-NECT-224, a first-in-human application of the latter radioligand was initiated to assess the general suitability of PET\/CT imaging in humans with a 64Cu-labeled bicyclic peptide directed to Nectin-4. Prospectively, the improved tumor-to-background contrasts achieved with the novel radioligands might further improve diagnostic accuracy and facilitate effective theranostic options in Nectin-4-expressing malignancies.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00366","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:18:01Z","timestamp":1787609881000},"page":"1887-1904","source":"Crossref","is-referenced-by-count":0,"title":["\u201cImaging\nTriplets on Two Wheels\u201d: 61Cu-, 64Cu-, and 68Ga-labeled\nBicyclic Peptides Targeting Nectin-4 Enable High-Contrast PET\nImaging of Urothelial Carcinoma and Triple-Negative Breast Cancer"],"prefix":"10.1021","volume":"37","author":[{"given":"Johanna","family":"Mauersberger","sequence":"first","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4467-3131","authenticated-orcid":true,"given":"Tobias","family":"Kro\u0308nke","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6104-6676","authenticated-orcid":true,"given":"Martin","family":"Ullrich","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Laube","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Brandt","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus at the Technische Universita\u0308t Dresden , , Fetscherstra\u00dfe 74 , ,","place":["Dresden, Germany, 01307"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pretze","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus at the Technische Universita\u0308t Dresden , , Fetscherstra\u00dfe 74 , ,","place":["Dresden, Germany, 01307"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Lohaus","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus at the Technische Universita\u0308t Dresden , , Fetscherstra\u00dfe 74 , ,","place":["Dresden, Germany, 01307"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hoberu\u0308ck","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus at the Technische Universita\u0308t Dresden , , Fetscherstra\u00dfe 74 , ,","place":["Dresden, Germany, 01307"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus at the Technische Universita\u0308t Dresden , , Fetscherstra\u00dfe 74 , ,","place":["Dresden, Germany, 01307"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Miederer","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]},{"name":"National Center for Tumor Diseases (NCT) , , ,","place":["Dresden, Germany, 01307"]},{"name":"German Cancer Research Center (DKFZ) , ,","place":["Heidelberg, Germany, 69120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]},{"name":"University Hospital Carl Gustav Carus at the Technische Universita\u0308t Dresden , , Fetscherstra\u00dfe 74 , ,","place":["Dresden, Germany, 01307"]},{"name":"German Cancer Consortium (DKTK) , , ,","place":["Dresden, Germany, 01307"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-5330","authenticated-orcid":true,"given":"Sven","family":"Stadlbauer","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]},{"name":"Technische Universita\u0308t Dresden , , Mommsenstra\u00dfe 4 , ,","place":["Dresden, Germany, 01069"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-1271","authenticated-orcid":true,"given":"Klaus","family":"Kopka","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]},{"name":"National Center for Tumor Diseases (NCT) , , ,","place":["Dresden, Germany, 01307"]},{"name":"German Cancer Consortium (DKTK) , , ,","place":["Dresden, Germany, 01307"]},{"name":"Technische Universita\u0308t Dresden , , Mommsenstra\u00dfe 4 , ,","place":["Dresden, Germany, 01069"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1610-1493","authenticated-orcid":true,"given":"Jens","family":"Pietzsch","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]},{"name":"Technische Universita\u0308t Dresden , , Mommsenstra\u00dfe 4 , ,","place":["Dresden, Germany, 01069"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-7111","authenticated-orcid":true,"given":"Robert","family":"Wodtke","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research , Bautzner Landstra\u00dfe 400 , ,","place":["Dresden, Germany, 01328"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"2026091607071901900_cit1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody-Drug Conjugates: Current\nStatus and Future Directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discovery\nToday"},{"key":"2026091607071901900_cit2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The Oncology Market for Antibody-Drug\nConjugates","volume":"20","author":"Do Pazo","year":"2021","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026091607071901900_cit3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical\nefficacy of FDA-approved antibody\u2013drug conjugates in human\ncancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"2026091607071901900_cit4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The\nJourney of Antibody-Drug Conjugates: Lessons Learned from 40 Years\nof Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discovery"},{"key":"2026091607071901900_cit5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug\nConjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"2026091607071901900_cit6","volume-title":"Fda\nApproved Antibody-Drug Conjugates (Adcs) by 2026 (Biopharma Peg)"},{"key":"2026091607071901900_cit7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The Anti-Nectin\n4: A Promising Tumor\nCells Target. A Systematic Review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol. Cancer\nTher."},{"key":"2026091607071901900_cit8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The Biology and Rationale of Targeting Nectin-4 in\nUrothelial Carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"2026091607071901900_cit9","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab\nVedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent\nTherapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"2026091607071901900_cit10","doi-asserted-by":"publisher","first-page":"43205","DOI":"10.1074\/jbc.M103810200","article-title":"Nectin4\/Prr4, a New Afadin-Associated\nMember of the Nectin Family\nThat Trans-Interacts with Nectin1\/Prr1 through V Domain Interaction","volume":"276","author":"Reymond","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2026091607071901900_cit11","volume-title":"Information for Padcev from European Medicines Agency"},{"key":"2026091607071901900_cit12","volume-title":"Fda Approves Enfortumab Vedotin-Ejfv with Pembrolizumab for Locally\nAdvanced or Metastatic Urothelial Cancer"},{"key":"2026091607071901900_cit13","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.3390\/molecules27217232","article-title":"Peptide-Drug Conjugates: A New Hope for Cancer Management","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"key":"2026091607071901900_cit14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","article-title":"Peptide-Drug Conjugates:\nAn Emerging Direction for the Next Generation of Peptide Therapeutics","volume":"67","author":"Dean","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s43018-025-01042-w","article-title":"Present and Future\nof Drug Conjugates\nfor Cancer Therapy","volume":"6","author":"Cazzamalli","year":"2025","journal-title":"Nat. Cancer"},{"key":"2026091607071901900_cit16","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3561","article-title":"Small molecule\u2013\nand peptide\u2013drug conjugates\naddressing integrins: A story of targeted cancer treatment","volume":"30","author":"Paulus","year":"2024","journal-title":"J. Pept. Sci."},{"key":"2026091607071901900_cit17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nchembio.184","article-title":"Phage-Encoded Combinatorial\nChemical Libraries Based on Bicyclic Peptides","volume":"5","author":"Heinis","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"2026091607071901900_cit18","doi-asserted-by":"publisher","first-page":"10187","DOI":"10.1021\/jm301276e","article-title":"Bicyclization\nand Tethering to Albumin Yields Long-Acting Peptide Antagonists","volume":"55","author":"Angelini","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit19","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1021\/acs.jmedchem.9b02129","article-title":"Identification and Optimization of\nEpha2-Selective Bicycles for the Delivery of Cytotoxic Payloads","volume":"63","author":"Mudd","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit20","doi-asserted-by":"publisher","first-page":"9858","DOI":"10.1021\/acs.jmedchem.2c00505","article-title":"Discovery and Optimization\nof a Synthetic Class of Nectin-4-Targeted Cd137 Agonists for Immuno-Oncology","volume":"65","author":"Upadhyaya","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit21","doi-asserted-by":"publisher","first-page":"21441","DOI":"10.1021\/acs.jmedchem.5c01378","article-title":"Design of Bicyclic\nPeptide Tandems Mimicking the Homodimeric\nGdf15 Protein to Inhibit Gdf15-Gfral-Ret Complex Cell Signaling","volume":"68","author":"Noisier","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit22","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1021\/acs.jmedchem.2c00065","article-title":"Discovery of Bt8009: A Nectin-4 Targeting Bicycle Toxin\nConjugate for the Treatment of Cancer","volume":"65","author":"Mudd","year":"2022","journal-title":"J. Med.\nChem."},{"key":"2026091607071901900_cit23","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","article-title":"Bt8009; a Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment\nof Solid Tumors","volume":"21","author":"Rigby","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"2026091607071901900_cit24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40291-025-00786-6","article-title":"Nectin-4-Targeting\nRadiotracers: Novel Theranostic Agents for Precision\nOncology in Cancer","volume":"29","author":"Speltri","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"2026091607071901900_cit25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The Molecular\nBlueprint of Targeted Radionuclide Therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026091607071901900_cit26","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.semnuclmed.2025.09.003","article-title":"Nectin-4,Bladder\nCancer, and Nuclear Medicine: A Theranostic\nFrontier","volume":"55","author":"Kabunda","year":"2025","journal-title":"Semin Nucl. Med."},{"key":"2026091607071901900_cit27","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.5c00469","article-title":"Immunopet Imaging of Nectin4 Expression\nin Gastric and Bladder Cancer Using [64cu]Cu-Nota-Padcev","volume":"22","author":"Huang","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026091607071901900_cit28","doi-asserted-by":"publisher","first-page":"102723","DOI":"10.1016\/j.xcrp.2025.102723","article-title":"A Zirconium-89-Labeled Antibody-Drug\nConjugate Pet Probe for Noninvasive\nMonitoring of Nectin4 Expression in Breast Cancer and Lung Cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Cell Rep. Phys. Sci."},{"key":"2026091607071901900_cit29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2967\/jnumed.125.270132","article-title":"[64cu]Cu-Nota-Ev-F(Ab\u2019)2 Enables Same-Day Immuno-Pet Imaging of Nectin-4 in Triple-Negative\nBreast and Urothelial Bladder Cancers","volume":"66","author":"Huang","year":"2025","journal-title":"J. Nucl.\nMed."},{"key":"2026091607071901900_cit30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12951-022-01444-3","article-title":"Nectin-4-Targeted\nImmunospect\/Ct Imaging and Photothermal Therapy of Triple-Negative\nBreast Cancer","volume":"20","author":"Shao","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"2026091607071901900_cit31","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11307-016-0953-x","article-title":"Preclinical\nEvaluation of an Anti-Nectin-4 Immunopet Reagent in Tumor-Bearing\nMice and Biodistribution Studies in Cynomolgus Monkeys","volume":"18","author":"Campbell","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"2026091607071901900_cit32","doi-asserted-by":"publisher","first-page":"21366","DOI":"10.1021\/acs.jmedchem.5c01260","article-title":"A Radiofluorinated\nNanobody Pet Tracer\nto Dynamically Visualize Differential Nectin4 Expression in Vivo","volume":"68","author":"Zheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2967\/jnumed.124.269024","article-title":"Pilot Study\nof Nectin-4-Targeted\nPet Imaging Agent 68ga-Fz-Nr-1 in Triple-Negative Breast\nCancer from Bench to First-in-Human","volume":"66","author":"Sun","year":"2025","journal-title":"J. Nucl.\nMed."},{"key":"2026091607071901900_cit34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1021\/acs.molpharmaceut.4c00858","article-title":"Preclinical Evaluation of an Al18f-Radiolabeled Bicyclic\nPeptide Targeting Nectin-4","volume":"22","author":"Duan","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026091607071901900_cit35","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.2967\/jnumed.123.266830","article-title":"Translational Pet Imaging of Nectin-4\nExpression in Multiple Different Cancers with 68ga-N188","volume":"65","author":"Zhang","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026091607071901900_cit36","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.molpharmaceut.4c00366","article-title":"Effects of\nPegylation on Imaging Contrast of 68ga-Labeled Bicyclic\nPeptide Pet Probes Targeting Nectin-4","volume":"21","author":"Wan","year":"2024","journal-title":"Mol.\nPharmaceutics"},{"key":"2026091607071901900_cit37","doi-asserted-by":"publisher","first-page":"107745","DOI":"10.1016\/j.bioorg.2024.107745","article-title":"A Cutting-Edge 68ga-Labeled\nBicyclic Peptide Pet Molecular Probe for Noninvasive Assessment of\nNectin4 Expression","volume":"152","author":"Ge","year":"2024","journal-title":"Bioorg. Chem."},{"key":"2026091607071901900_cit38","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human Study of the Radioligand 68ga-N188 Targeting\nNectin-4 for Pet\/Ct Imaging of Advanced\nUrothelial Carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026091607071901900_cit39","doi-asserted-by":"publisher","first-page":"21962","DOI":"10.1021\/acs.jmedchem.5c02371","article-title":"\u201cPrecision\non\nTwo Wheels\u201d - Structural Refinement of 64cu- and 68ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved\nTumor Imaging: From Preclinical Development to First-in-Human Application","volume":"68","author":"Kro\u0308nke","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ph19020321","article-title":"Coppernostics-Here\nWe Are Now, Entertain Us!","volume":"19","author":"Bru\u0308hlmann","year":"2026","journal-title":"Pharmaceuticals"},{"key":"2026091607071901900_cit41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2407-7-73","article-title":"Nectin-4 Is a New Histological\nand Serological Tumor Associated Marker for Breast Cancer","volume":"7","author":"Fabre-Lafay","year":"2007","journal-title":"BMC Cancer"},{"key":"2026091607071901900_cit42","doi-asserted-by":"publisher","first-page":"19543","DOI":"10.1074\/jbc.M410943200","article-title":"Nectin-4,\na New Serological Breast\nCancer Marker, Is a Substrate for Tumor Necrosis Factor-Alpha-Converting\nEnzyme (Tace)\/Adam-17","volume":"280","author":"Fabre-Lafay","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2026091607071901900_cit43","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1074\/jbc.M116.746859","article-title":"Ectodomain\nShedding of the Cell Adhesion\nMolecule Nectin-4 in Ovarian Cancer Is Mediated by Adam10 and Adam17","volume":"292","author":"Buchanan","year":"2017","journal-title":"J. Biol. Chem."},{"key":"2026091607071901900_cit44","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin\nin Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026091607071901900_cit45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced\nUrothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026091607071901900_cit46","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in Nectin4 Expression\nacross Molecular Subtypes of Urothelial Cancer Mediates Sensitivity\nto Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2026091607071901900_cit47","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous\nNectin-4 Expression Frequently Decreases During Metastatic Spread\nof Urothelial Carcinoma and Is Associated with Enfortumab Vedotin\nResistance","volume":"29","author":"Klu\u0308mper","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026091607071901900_cit48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady1111","article-title":"Nectin-4 Pet\nfor Predicting Enfortumab Vedotin Dose-Response in Urothelial Carcinoma","volume":"12","author":"Mishra","year":"2026","journal-title":"Sci. Adv."},{"key":"2026091607071901900_cit49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1021\/acs.bioconjchem.6c00056","article-title":"Linker Chemistry in Radiopharmaceutical Design","volume":"37","author":"Stoddard","year":"2026","journal-title":"Bioconjugate Chem."},{"key":"2026091607071901900_cit50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1158\/0008-5472.CAN-18-0238","article-title":"Bicyclic Peptides as a New Modality\nfor Imaging and Targeting of Proteins Overexpressed by Tumors","volume":"79","author":"Eder","year":"2019","journal-title":"Cancer Res."},{"key":"2026091607071901900_cit51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fmed.2019.00200","article-title":"Nectin-4 Expression\nIs an Independent Prognostic Biomarker and Associated with Better\nSurvival in Triple-Negative Breast Cancer","volume":"6","author":"Zeindler","year":"2019","journal-title":"Front.\nMed."},{"key":"2026091607071901900_cit52","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.3390\/cancers15092565","article-title":"Diagnostic and Prognostic Roles of Urine Nectin-2 and\nNectin-4 in Human Bladder Cancer","volume":"15","author":"Miyake","year":"2023","journal-title":"Cancers"},{"key":"2026091607071901900_cit53","doi-asserted-by":"publisher","first-page":"8089","DOI":"10.1021\/jm4011753","article-title":"Selective Arylsulfonamide Inhibitors\nof Adam-17: Hit Optimization and Activity in Ovarian Cancer Cell Models","volume":"56","author":"Nuti","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026091607071901900_cit54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4161\/cbt.5.6.2707","article-title":"Selective Inhibition of Adam Metalloproteases Blocks\nHer-2 Extracellular Domain (Ecd) Cleavage and Potentiates the Anti-Tumor\nEffects of Trastuzumab","volume":"5","author":"Liu","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"2026091607071901900_cit55","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1096\/fj.201700823RR","article-title":"The Metalloprotease\nAdam10 (a Disintegrin and Metalloprotease 10) Undergoes Rapid, Postlysis\nAutocatalytic Degradation","volume":"32","author":"Brummer","year":"2018","journal-title":"FASEB J."},{"key":"2026091607071901900_cit56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13550-025-01361-0","article-title":"Biodistribution,\nDosimetry, and Preliminary Imaging\nof the Novel Nectin-4-Targeting Pet Tracer [68ga]Ga-Fz-Nr-1\nin Humans","volume":"16","author":"Shi","year":"2026","journal-title":"EJNMMI Res."},{"key":"2026091607071901900_cit57","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2967\/jnumed.123.266171","article-title":"61cu-Labeled Radiotracers:\nAlternative or\nChoice?","volume":"64","author":"Fani","year":"2023","journal-title":"J. Nucl. Med."},{"key":"2026091607071901900_cit58","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00259-025-07301-3","article-title":"First-in-Human\nAdministration\nof [61cu]Cu-Nodaga-Lm3 and Head-to-Head Comparison with\n[(68)Ga]Ga-Dota-Toc Pet\/Ct as Part of the Phase I\/Ii Copper Pet in\nNet Study","volume":"53","author":"Nicolas","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026091607071901900_cit59","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s00259-004-1756-x","article-title":"Dosimetry of 60\/61\/62\/64cu-Atsm: A Hypoxia Imaging Agent for Pet","volume":"32","author":"Laforest","year":"2005","journal-title":"Eur.\nJ. Nucl. Med. Mol. Imaging"},{"key":"2026091607071901900_cit60","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00259-005-1906-9","article-title":"A Comparison\nof Pet Imaging Characteristics of Various Copper Radioisotopes","volume":"32","author":"Williams","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026091607071901900_cit61","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bju.16901","article-title":"Staging Metastatic\nUrothelial Cancer\nwith Nectin-4 Imaging Using Gallium-68-N188 Pet\/Ct","volume":"137","author":"Miederer","year":"2026","journal-title":"BJU Int."},{"key":"2026091607071901900_cit62","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1007\/s00259-025-07609-0","article-title":"A Pilot Study\nof Nectin-4-Targeted Radioligand [68ga]Ga-Fznr-1 in Patients\nwith Pancreatic Ductal Adenocarcinoma: Head-to-Head Comparison with\n[18f]-Fdg","volume":"53","author":"Jiang","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"key":"2026091607071901900_cit63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/instruments3010009","article-title":"Introduction of the New Center for Radiopharmaceutical\nCancer Research at Helmholtz-Zentrum Dresden-Rossendorf","volume":"3","author":"Kreller","year":"2019","journal-title":"Instruments"},{"key":"2026091607071901900_cit64","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.apradiso.2012.01.019","article-title":"Module-Assisted Preparation of 64cu with\nHigh Specific Activity","volume":"70","author":"Thieme","year":"2012","journal-title":"Appl.\nRadiat. Isot."},{"key":"2026091607071901900_cit65","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.apradiso.2012.11.007","article-title":"High Specific\nActivity 61cu Via 64zn(P,Alpha)61cu Reaction at Low Proton Energies","volume":"72","author":"Thieme","year":"2013","journal-title":"Appl. Radiat.\nIsot."},{"key":"2026091607071901900_cit66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41181-023-00233-z","article-title":"Production of the Pet\nRadionuclide 61cu Via the 62ni(P,2n)61cu Nuclear Reaction","volume":"9","author":"Bru\u0308hlmann","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"2026091607071901900_cit67","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/acs.jmedchem.1c01791","article-title":"\u201cClickable\u201d Albumin Binders for Modulating\nthe Tumor Uptake of Targeted Radiopharmaceuticals","volume":"65","author":"Brandt","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00366","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/9\/1887\/67105286\/acs.bioconjchem.6c00366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/9\/1887\/67105286\/acs.bioconjchem.6c00366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:17:41Z","timestamp":1789557461000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/9\/1887\/5298068\/Imaging-Triplets-on-Two-Wheels-61Cu-64Cu-and-68Ga"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":67,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,22]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00366","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}